Position: Board member since 2014 and Chairman of the Board since 2020.

Education: Ph.D. in Genetics from Umeå University.

Board Committees: Member of the Remuneration Committee.

Experience: Former head of Life Science Investments at Industrifonden. He has more than 25 years’ experience from the pharma and biotech industry in executive positions at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB.

Other current assignments: Member of the Board of Medivir Aktiebolag. Chairman of the Board of Sixera Pharma AB, QureTech Bio AB, Omnio AB and Ignitus AB.

Independent/Dependent of the company/major owners: Independent in relation to the company and its management and in relation to major shareholders.

Holdings in Cinclus Pharma: Ordinary shares: 1,084,771 (via related parties).

Position: Board member since 2017.

Education: Master of Laws (LL.M.) from Uppsala University.

Board Committees: Chairman of the Remuneration Committee.

Experience: More than 20 years’ experience as a business lawyer, focusing entirely on advising clients within the life sciences industry on matters of commercial and corporate law. Previous work experience includes law firms Mannheimer Swartling, Lindahl and Bird & Bird. Since 2006 working for his own company IARU.

Other current assignments: Member of the Board of Xspray Pharma AB (publ) and IARU Institutet för Affärsjuridisk Rådgivning i Uppsala AB.

Independent/Dependent of the company/major owners: Independent in relation to the company and its management and in relation to major shareholders.

Holdings in Cinclus Pharma: Ordinary shares: 94,435 (via related parties).

Position: Board member since 2021.

Education: Master in Finance and Business Administration from Stockholm School of Economics.

Board Committees: Chairman of the Audit Committee.

Experience: More than 20 years of experience within asset management and equity markets from SEB, Nordea, Odin Funds and Neonet Securities. Entrepreneurial experience from building and running Nordic Investor Services, an advisory consultant within global corporate governance, since 2002.

Other current assignments: Chairman of the Board in Factoringgruppen AB and Caroline Svedbom AB. Stendörren Fastigheter AB (publ) and Occlutech AG.

Independent/Dependent of the company/major owners: Independent in relation to the company and its management and in relation to major shareholders.

Holdings in Cinclus Pharma: Ordinary shares: 50,270 (own and via related parties).

Position: Board member since 2022.

Education: Ph.D. in Molecular Neurobiology and Master of Science in Biomedicine. Both from Karolinska Institutet.

Board Committees: Member of the Audit Committee.

Experience: Currently Partner and Co-Head at Trill Impact Ventures. Previous experience includes the roles of Head of life science at Industrifonden, Vice President, Strategy and Ventures at Gambro, and management consulting at Boston Consulting Group in Stockholm and New York.

Other current assignments: Member of the Board of Emerging Health Ventures I AB and serves on the board of Stockholms Sjukhem.

Independent/Dependent of the company/major owners: Independent in relation to the company and its management and in relation to major shareholders.

Holdings in Cinclus Pharma: -

Position: Board member since 2016.

Education: Pharmacist, Ph.D of Pharmacy (pharma-cognosy), Adjunct Professor at Uppsala University.

Board Committees: Member of the Audit Committee.

Experience: Former Head of pharmacology at Pharmacia & Upjohn; VP clinical trials Quintiles Europe, CEO of Quintiles Scandinavia. Chairman of Aprea Therapeutics AB, Denator AB and Aprea Personal AB. Board member of Swedish Match AB, SOBI AB, Recipharm AB, Smartfish AB, Moberg Pharma AB, TFS Trial Form Support International AB, Apotek Produktion & Laboratorier AB and Industrifonden. Chairman Bionor Pharma AS and Chairman i BioArctic AB. Chairman of the Board of Index Pharmaceutical Holding AB.

Other current assignments: CEO and Member of the Board of Rolfsen Consulting AB. Partner in Serendipity Partners.

Independent/Dependent of the company/major owners: Independent in relation to the company and its management and in relation to major shareholders.

Holdings in Cinclus Pharma: Ordinary Shares: 23,290 (own).

Position: Board member since 2014.

Education: MD. Ph.D. Gastroenterologist and Internal Medicine and Hepatology from Karolinska Institutet.

Experience: 27 years of Clinical experience. Consultant at AstraZeneca and former VP at Novartis. Innovated the modern principles for H. pylori eradication therapy, currently state-of-the-art.

Other current assignments: Chairman of the Board of PetoMaj Invest AB and Cinclus Pharma AG.

Independent/Dependent of the company/major owners: Not independent in relation to the company and its management. Independent in relation to major shareholders.

Holdings in Cinclus Pharma: Ordinary shares: 2,050,015 (own and via related parties).

Position: Board member since 2016.

Education: Master of Medical Sciences and Clinical Drug Development from Uppsala University.

Experience: More than 15 years experience from drug development and medical affairs within the pharmaceutical industry. He has held a broad spectrum of positions within clinical development, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen, Shire and Novartis. Currently Medical Director for Northern Europe at PTC Therapeutics.

Other current assignments: Member of the Board of Regulus Pharma Fas 1 AB.

Independent/Dependent of the company/major owners: Independent in relation to the company and its management and in relation to major shareholders.

Holdings in Cinclus Pharma: Ordinary shares: 24,083 (own).